Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D002986:Clinical Trials as Topic; D004878:Ergotamine / Q000494:pharmacology; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000145:classification / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D010919:Placebos; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013565:Sympatholytics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013575:Syncope / Q000139:chemically induced; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D007211:Indoles; D010919:Placebos; D013565:Sympatholytics; D004878:Ergotamine